In preclinical studies, Celgosivir has demonstrated strong synergy with interferon-alpha with and without ribavirin and has the potential to be included as part of a combination therapeutic approach to improve efficacy and/or tolerability.
A recently completed phase IIa monotherapy study demonstrated that the drug was well tolerated with some evidence of antiviral activity in treatment-naive chronic HCV patients.
“With the large market potential and unmet need in current hepatitis C treatment, Celgosivir is an important component of our value proposition in the short-term. Based on its strong demonstration of synergy in non-clinical studies to date, Celgosivir shows great promise as part of a combination therapy approach to improving the success of treatment for patients suffering from chronic hepatitis C infections,” said Dr Jim DeMesa, president and CEO of Migenix.